In setback for biopharma, Senate version of Trump's tax bill drops Orphan Cures Act
The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend an Inflation Reduction Act provision currently affecting treatments for rare diseases.
